TIDMCOS

RNS Number : 3589X

Collagen Solutions PLC

28 August 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Joins consortium developing new treatments for Parkinson's disease

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been chosen to participate in a new research project to develop novel treatments for Parkinson's disease.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at NUI Galway, who have secured EUR4 million in funding through the European Horizon 2020 grant programme. The project, entitled 'Development of Biomaterial-based Delivery Systems for Parkinson's disease - an Integrated Pan-European Approach', facilitates collaboration between world class researchers and industry partners to develop the first disease-modifying therapy for Parkinson's, which could slow down the progression of the disease rather than offering mere symptomatic benefits

As a key member of the consortium, Collagen Solutions will receive significant funding to develop various types of medical grade collagens for investigation over the duration of the project.

Dr Stewart White, CEO of Collagen Solutions plc commented: "Collagen Solutions is delighted to be part of such an esteemed consortium working on developing new therapies for such a devastating condition. I believe our shared success as part of the consortium provides further validation of the Company's reputation for developing and suppling consistent high quality medical grade collagen products for its international clients. Our R&D capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project."

Professor Abhay Pandit, Director of CÚRAM, stated that: "CÚRAMs strength lies in establishing unique networks of synergistic national and international collaborations, integrating world class clinical, academic and industrial partners. Collagen Solutions' ability to source, develop and manufacture collagen components for therapeutic use will be critical in meeting the requirements for a functional delivery formulation for the project. It is a mark of quality for all involved to have secured this grant funding, and we are very pleased to welcome Collagen Solutions to the consortium."

Enquiries:

 
 Collagen Solutions Plc 
 David Evans, Chairman                Tel: 07881 484 785 
 Stewart White, CEO                   Tel: 0141 558 2008 
 
 Panmure Gordon & Co (Joint            Tel: 0207 8862 714 
  Broker)                               Tel: 020 7886 2905 
  Robert Naylor (Corporate Finance) 
  Maisie Atkinson (Corporate 
  Broking) 
 
 Walbrook PR Ltd                      Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Anna Dunphy                          Mob: 07876 741 001 
 Mike Wort                            Mob: 07900 608 002

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPGUWCRUPAGAM

(END) Dow Jones Newswires

August 28, 2015 02:00 ET (06:00 GMT)

Healthcare Inv (LSE:HIO)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Healthcare Inv Charts.
Healthcare Inv (LSE:HIO)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Healthcare Inv Charts.